NASDAQ:CLLS
Cellectis S.A. Stock News
$2.99
-0.0499 (-1.64%)
At Close: May 17, 2024
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022
08:31pm, Thursday, 12'th May 2022 GlobeNewswire Inc.
◦ UCART20x22 preclinical data presented at AACR demonstrated PoC with robust in vitro and in vivo anti-tumor activity
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
08:43pm, Tuesday, 10'th May 2022 GlobeNewswire Inc.
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)
Monthly information on share capital and company voting rights
08:43pm, Tuesday, 10'th May 2022 GlobeNewswire Inc.
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Cellectis annonce ses résultats financiers pour le premier trimestre 2022
08:42pm, Thursday, 05'th May 2022 GlobeNewswire Inc.
NEW YORK, 05 mai 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génom
Cellectis to Report First Quarter 2022 Financial Results
08:40pm, Thursday, 05'th May 2022 GlobeNewswire Inc.
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to
Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results
08:14pm, Thursday, 05'th May 2022 GlobeNewswire Inc.
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-s
Cellectis to Report First Quarter 2022 Financial Results
04:40pm, Thursday, 05'th May 2022
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to d
Cellectis reçoit une note convertible de 20 millions de dollars dans le cadre de l’accord de collaboration avec son partenaire Cytovia Therapeutics
06:44am, Wednesday, 27'th Apr 2022 GlobeNewswire Inc.
Cellectis Receives $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics
06:44am, Wednesday, 27'th Apr 2022 GlobeNewswire Inc.
NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platfor
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform
NEW YORK, 08 avr. 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de géno
Iovance (IOVA) Stock Rallies 33% in a Month: Here's Why
07:17pm, Friday, 08'th Apr 2022 Zacks Investment Research
Iovance (IOVA) to complete the FDA filing for its lead candidate in melanoma by August. It will start a clinical study for its first TALEN-edited TIL therapy for two advanced cancer indications later
Monthly information on share capital and company voting rights
08:30pm, Thursday, 07'th Apr 2022 GlobeNewswire Inc.
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
08:30pm, Thursday, 07'th Apr 2022 GlobeNewswire Inc.
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)
Allogene: Speculative CAR T Biotech With Big Potential In Oncology
10:54pm, Friday, 01'st Apr 2022
Allogene: Speculative CAR T Biotech With Big Potential In Oncology
